Global investigational new drug CDMO market to reach USD 6.7 billion by 2027. Global investigational new drug CDMO market is valued approximately at USD 4.2 billion in 2020 and is anticipated to grow with a healthy growth rate of about 6.9% over the forecast period 2021-2027. A CDMO (contract development and manufacturing company) refers to a company within the pharmaceutical industry which offers drug manufacturing and development services. Companies active in the pharmaceutical sector partner with contract development and manufacturing company in order to outsource drug manufacturing and drug development. The global investigational new drug CDMO market is being driven by increasing outsourcing services by pharmaceutical companies and growing pharmaceutical industry across the globe. Furthermore, rising investment in research and development will provide new opportunities for the global investigational new drug CDMO industry. According to Statista, the total spending on pharmaceutical research and development across the globe is expected to increase from USD 137 billion in 2012 to approximately USD 254 billion by 2026. Such growth in the spending on pharmaceutical research and development across the globe is expected to increase the adoption of contract development and manufacturing for drug development and hence this is expected to boost the market growth. However, compliance issues while outsourcing may impede market growth over the forecast period of 2021-2027.

The regional analysis of the global investigational new drug CDMO market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America accounts for the largest share in terms of market revenue in the global investigational new drug CDMO market over the forecast period 2021-2027. Factors such as increased research and development investments by pharmaceutical and life sciences companies, increase in the prevalence of a range of diseases and disorders, initiatives for drug development and manufacturing across countries such as the United States and Canada, etc. contribute towards the largest market share of the region in the forecast years.

Major market player included in this report are:
Covance Inc.
Charles River Laboratories Inc.
Cambrex Corporation
IQVIA Holdings Inc.
Syneos Health
Lonza
Catalent
Recipharm AB
Siegfried Holding AG
Thermo Fisher Scientific Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:
Small Molecule
Large Molecule
By Service:
Contract Development
Contract Manufacturing
By End-User:
Pharmaceutical Companies
Biotech Companies
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019
Base year - 2020
Forecast period - 2021 to 2027.

Target Audience of the Global Investigational New Drug CDMO Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors